Miltenyi Biotec

24 articles about Miltenyi Biotec

• Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®

  12/18/2023

  Replay today announced a licensing and manufacturing agreement to support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy targeting the tumor-associated neoantigen, PRAME.

• Miltenyi Biotec acquires biosensor company lino Biotech

  3/15/2023

  lino Biotech announced it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.

• Miltenyi Biotec offers automated and closed adherent cell culture solutions on CliniMACS Prodigy®

  7/14/2020

  Miltenyi Biotec announced the immediate availability of its new CliniMACS Prodigy® Adherent Cell Culture System.

• Miltenyi Biotec launches world’s first fully automated light sheet microscope

  5/28/2020

  Miltenyi Biotec today announces the UltraMicroscope Blaze.

• 

  Biotech Bay Companies Fighting Against COVID-19

  5/26/2020

  Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.

• Miltenyi Biotec launches new tool for coronavirus-specific T cell research

  4/1/2020

  Miltenyi Biotec today launches the SARS-CoV-2 PepTivator Peptide Pools, a new addition to its popular PepTivator Portfolio specifically developed to help researchers currently investigating COVID-19.

• IsoPlexis Continues Progress on Precision CAR-T cell Characterization with Recent Data Sets & Miltenyi Biotec, Inc. Technology Note

  9/26/2019

  IsoPlexis illustrates progress in CAR-T development & bioprocessing with funding, recent data sets, and co-marketing technology note with Miltenyi Biotec, Inc.

• Cellenion and Miltenyi Biotec Sign Co-Marketing Agreement to Provide a Time and Cost-Efficient Solution for the Development of Monoclonal Cell Lines

  7/12/2018

  SCIENION AG and Miltenyi Biotec GmbH today announced that Scienion’s affiliate Cellenion and Miltenyi Biotec have signed a co-marketing agreement.

• Lentigen Technology, A Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma

  7/20/2017

• After Filling 70 U.S. Positions This Year, Miltenyi Biotec Plans to Add 30 More U.S. Jobs in 2017

  12/2/2016

• Miltenyi Biotec, Inc. Webinar Spotlights Advances In Translational And Basic T Cell Research

  6/14/2016

• Miltenyi Biotec, Inc. And Cesca Therapeutics' Subsidiary Totipotentrx Announce Multi-Year Commercial Agreement For Bone Marrow Transplantation

  10/28/2015

• Miltenyi Biotec, Inc. Acquires Gene Therapy Assets From Lentigen Corporation

  8/14/2014

• Miltenyi Biotec, Inc. Receives FDA Approval For Clinimacs® CD34 Reagent System For Prevention Of Graft-Versus-Host Disease In The Treatment Of Acute Myeloid Leukemia

  1/24/2014

• Miltenyi Biotec, Inc. Acquires Owl biomedical, Inc.

  4/23/2013

• Miltenyi Biotec, Inc. Partners With Terso Solutions, Inc. for a Fully Automated, On-Site Inventory Management Program

  4/3/2013

• Automated Cell Biology Workflows with Tecan And Miltenyi Biotec, Inc.

  8/17/2010

• Miltenyi Biotec, Inc.: Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial "PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells

  10/29/2009

• Miltenyi Biotec, Inc.'s Advanced Bag Design for Cryopreservation: The New CryoMACS(R) Freezing Bag

  7/14/2009

• Miltenyi Biotec, Inc.'s Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings

  5/20/2009